BRAF/MEK inhibitors in the treatment of malignant melanoma

03/2018

Prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA

Dermatovenerologická klinika 3. LF UK a Fakultní nemocnice Královské Vinohrady, Praha

SUMMARY

Metastatic melanoma was still relatively recently considered as a malignant tumor with a very poor prognosis, with only limited response to the available treatment methods. However, over the last five years, at least in part of the patients, metastatic melanoma has been slowly changing from being a disease with poor prognosis to disease with long-term survival. It is mostly due to new therapeutic options. Ten years ago, five-year survival rate was no more than 10% of patients. Nowadays, using the latest therapeutic options, the number is approximately 30%.

KEY WORDS

metastatic malignant melanoma, BRAF inhibitors, MEK inhibitors, survival